Literature DB >> 16460132

Better analysis for better decisions: has pharmacoeconomics come of age?

Michael Drummond, Mark Sculpher.   

Abstract

Mesh：

Year:  2006        PMID： 16460132     DOI： 10.2165/00019053-200624020-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  12 in total

1.  Modeling for health care and other policy decisions: uses, roles, and validity.

Authors:  M C Weinstein; E L Toy; E A Sandberg; P J Neumann; J S Evans; K M Kuntz; J D Graham; J K Hammitt
Journal:  Value Health       Date:  2001 Sep-Oct       Impact factor: 5.725

2.  Using economic evaluations to make formulary coverage decisions. So much for guidelines.

Authors:  A H Anis; Y Gagnon
Journal:  Pharmacoeconomics       Date:  2000-07       Impact factor: 4.981

3.  Using multilevel models for assessing the variability of multinational resource use and cost data.

Authors:  Richard Grieve; Richard Nixon; Simon G Thompson; Charles Normand
Journal:  Health Econ       Date:  2005-02       Impact factor: 3.046

Review 4.  Review of guidelines for good practice in decision-analytic modelling in health technology assessment.

Authors:  Z Philips; L Ginnelly; M Sculpher; K Claxton; S Golder; R Riemsma; N Woolacoot; J Glanville
Journal:  Health Technol Assess       Date:  2004-09       Impact factor: 4.014

5.  Country specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: the Canadian ASSENT-3 economic analysis.

Authors:  Andrew R Willan; Eleanor M Pinto; Bernie J O'Brien; Padma Kaul; Ron Goeree; Larry Lynd; Paul W Armstrong
Journal:  Health Econ       Date:  2005-04       Impact factor: 3.046

Review 6.  Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.

Authors:  Marco Barbieri; Michael Drummond; Richard Willke; Jeremy Chancellor; Bruno Jolain; Adrian Towse
Journal:  Value Health       Date:  2005 Jan-Feb       Impact factor: 5.725

Review 7.  Intergenerational equity: an exploration of the 'fair innings' argument.

Authors:  A Williams
Journal:  Health Econ       Date:  1997 Mar-Apr       Impact factor: 3.046

8.  Incorporating societal concerns for fairness in numerical valuations of health programmes.

Authors:  E Nord; J L Pinto; J Richardson; P Menzel; P Ubel
Journal:  Health Econ       Date:  1999-02       Impact factor: 3.046

9.  Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty--when is there sufficient evidence?

Authors:  Mark Sculpher; Karl Claxton
Journal:  Value Health       Date:  2005 Jul-Aug       Impact factor: 5.725

Review 10.  Bayesian methods for evidence synthesis in cost-effectiveness analysis.

Authors:  A E Ades; Mark Sculpher; Alex Sutton; Keith Abrams; Nicola Cooper; Nicky Welton; Guobing Lu
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981
View more
  1 in total

1.  The value of health care--a matter of discussion in Germany.

Authors:  Franz Porzsolt; Moritz Ackermann; Volker Amelung
Journal:  BMC Health Serv Res       Date:  2007-01-02       Impact factor: 2.655
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.